Molecularly targeted therapy may not suit every pa
Although the molecular targeted therapy for breast cancer distinguishes itself with a significant breakthrough, yet the method was only indicated for the Her2 positive cases. This was learnt by our reporter at the conference of standardization of Her2 detection.
Literature records aboard showed that among the cases of breast cancers, the medium positive rate of Her2 was 25 % -30 % and the highly positive rate was 14 %. Domestically, there is as yet no definite data.
Her2 is human epithelial growth factor receptor-2 and is a kind of protooncogene, which plays a key role during the transmission route of the signal of cellular growth factor and the control of normal cellular growth and their division. Her-2 is a gene related to invasive cancer cell growth, with an expression leading to an uncontrolled growth of the cancer cells resulting in the recurrence and metastasis of the tumor which shortens the survival period of the patients.
Professor Jiang Zhefei of army No. 307 hospital said that targeted biological gene worked through gene selection, aiming directly at killing the malignant cancer cells without affecting the survival of normal cells, thus the side effects of the therapy were lessened, relieving the sufferings of the patients and finally improved the patient's quality of life and effectively prolonged the survival period of the patients. At present, the target molecule (Her2) directly aiming at the treatment of breast is a monoclonal antibody, however, its use is limited only for Her2++ or Her2+++ patients. Therefore, for the treatment of patients with breast cancer, the decision of using targeted biological therapy depends upon a positive result of the Her2 test, the detection of which appears to be a key point of importance., http://www.100md.com
Literature records aboard showed that among the cases of breast cancers, the medium positive rate of Her2 was 25 % -30 % and the highly positive rate was 14 %. Domestically, there is as yet no definite data.
Her2 is human epithelial growth factor receptor-2 and is a kind of protooncogene, which plays a key role during the transmission route of the signal of cellular growth factor and the control of normal cellular growth and their division. Her-2 is a gene related to invasive cancer cell growth, with an expression leading to an uncontrolled growth of the cancer cells resulting in the recurrence and metastasis of the tumor which shortens the survival period of the patients.
Professor Jiang Zhefei of army No. 307 hospital said that targeted biological gene worked through gene selection, aiming directly at killing the malignant cancer cells without affecting the survival of normal cells, thus the side effects of the therapy were lessened, relieving the sufferings of the patients and finally improved the patient's quality of life and effectively prolonged the survival period of the patients. At present, the target molecule (Her2) directly aiming at the treatment of breast is a monoclonal antibody, however, its use is limited only for Her2++ or Her2+++ patients. Therefore, for the treatment of patients with breast cancer, the decision of using targeted biological therapy depends upon a positive result of the Her2 test, the detection of which appears to be a key point of importance., http://www.100md.com